About Abcentra

Company Overview

Abcentra, formerly Cardiovax, is a clinical stage biopharmaceutical company that addresses unmet needs in inflammation with monoclonal antibodies to a novel drug target, oxidized low density lipoprotein (oxLDL).The company’s core technology, developed at Cedars-Sinai Medical Center and Lund University, builds upon three decades of research related to the role of inflammation in cardiovascular disease (CVD), and allows for targeting inflammation via a novel mechanism that is independent of immunosuppression. The company has been operating since 2006 with Dr. PK Shah (Cedar-Sinai) and Dr. Jan Nilsson (Lund University), the inventors of the technology, leading its research.

Abcentra is developing a pipeline of therapeutic monoclonal antibodies against oxLDL, a prolific mediator of inflammation that is relevant to CVD, rheumatic disease, and cancer. OxLDL is cited in more than 8000 scientific publications for its role as a mediator of inflammation, and years of Abcentra’s research has now allowed for direct targeting of this molecule. By targeting oxLDL, Abcentra develops new biological drugs that treat inflammation-driven diseases without the side effects and safety concerns (infections and cancers) associated with current therapies, which target inflammation systemically.

The company’s lead product, orticumab, is being developed to treat plaque psoriasis and accelerated atherosclerosis in patients with rheumatoid arthritis (RA). Orticumab has been evaluated in three clinical trials and been administered to more than 200 patients with an excellent safety profile—no serious side effects related to the drug. It is currently being manufactured for clinical trials.

In addition to the clinical development of orticumab, Abcentra has a preclinical program focused on new monoclonal antibody treatments to lower lipoprotein(a) [or lp(a)] and research programs including active vaccine candidates for CVD and other inflammation-related diseases.

Board of Directors

Strategic Advisors